ReCor Medical

Recor Medical is a medical technology company focused on transforming the management of hypertension through its FDA-approved Paradise Ultrasound Renal Denervation (uRDN) system. The Paradise system uses 360-degree ultrasound energy to ablate renal nerves in 7-second treatment cycles, delivering clinically proven blood pressure reductions sustained across multiple years in patients with uncontrolled or resistant hypertension. As a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., Recor sells to interventional cardiologists and hospital catheterization labs in the United States and internationally, where the system also bears CE mark approval. The company has conducted multiple successful U.S. randomized controlled trials (RADIANCE-HTN series) and obtained a CMS National Coverage Determination, establishing a reimbursement pathway for routine clinical adoption.